European PRAC concludes benefits of ifosfamide solutions continue to outweigh risks

Two recent studies suggested the known risk of encephalopathy is higher with the solution than with the powder form. The PRAC concluded this could not be excluded and has recommended the existing warning be updated with the latest information on this side effect.

European Medicines Agency